Loading...
•
Mar 31, 2024
Arcus Biosciences Q1 2024 Earnings Report
Arcus Biosciences reported financial results for Q1 2024 and provided a pipeline update.
Key Takeaways
Arcus Biosciences reported Q1 2024 financial results, including revenues of $145 million and a net loss of $4 million. The company highlighted its strong cash position of $1.1 billion, expected to fund operations into 2027, and advancements in its pipeline with upcoming data presentations at ASCO and expected completion of enrollment for Phase 3 studies.
Arcus will disclose data in two oral presentations at ASCO 2024, including updated data from EDGE-Gastric and data from ARC-9.
Data from the casdatifan 100 mg expansion cohort of ARC-20 are expected to be presented in the second half of 2024.
Completion of enrollment for the Phase 3 studies STAR-221 and STAR-121 is expected by mid-year and the second half of 2024, respectively.
Arcus is well-positioned to advance its pipeline with $1.1 billion in cash, cash equivalents, and marketable securities, providing runway into 2027.
Revenue by Segment
Forward Guidance
Arcus expects cash, cash equivalents and marketable securities to be between $870 million and $920 million at the end of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...